Invited Speakers

 

 

Marion Peters

2025 William H. Prusoff HEP DART Lifetime Achievement Award Recipient

University of California, San Francisco, USA

 

Academic Speakers

 
 

Homie Razavi

Centers for Disease Analysis Foundation, USA

"Plenary Lecture: Progress towards Hepatitis B and C Elimination"

Natasha Martin

UC San Diego, USA

"Economic impact and elimination strategies for HCV and HBV"

Mariam Levy

Liverpool Hospital and UNSW, Australia

"Hepatitis elimination is not achievable without a SEARCH"

Pietro Lampertico

University of Milan, Italy

"The HDV epidemic – is the problem bigger or smaller than we think and will this affect the treatment landscape? "

 

Manal 

El-Sayed

Aims Sans University, Egypt

"Plenary Lecture: status of Obesity and MASLD in Africa and America"

Tatyana Kushner

Weill Cornell Medicine, USA

"Updates in Guidance and Approach to HBV and HCV in pregnant people - critical population for our Path To HBV/HCV Elimination"

Laura Malone

World Hepatitis Alliance, Switzerland

"Impact and importance of involving people with lived experience and community groups in drug development processes"

Barbara Testoni

Lyons University, France

"Plenary Lecture:Basic research for Hepatitis B infections"

 

Mark Sulkowski

Johns Hopkins University, USA

"Novel antivirals for HBV functional cure"

Yuen Man-Fung

Hong Kong University, Hong Kong

"Special Lecture: Novel biomarkers in HBV cure, and endpoints"

Charles Flexner

Johns Hopkins University, USA

"Plenary Lecture: Long-acting injectables for HBV & HCV: a key to elimination"

Jordan Feld

University of Toronto, Canada

"Using CHIM (Controlled Human Infection Model) to accelerate HCV vaccine development"

 

Andrea Cox

Johns Hopkins University, USA

"HBV vaccines in people living with HIV and current HCV vaccine efforts"

Laurence Sperling

Emory University, USA

"Plenary Lecture:MASLD and cardiovascular disease"

Veronica Miller

University of California Berkeley, USA

"Reasonably likely surrogate endpoint for MASH - road to validation"

Arun Sanyal

Virginia Commonwealth University, USA

"GLP-1s  and combination— the impact of these drugs cannot be understated and will influence future drug development for MASLD/MASH"

 

Stanley Lemon

University of North Carolina Chapel Hill, USA

"Cellular host factors required for hepatitis A virus infection"

Michael Manns

Hannover Medical School, Germany

"Primary sclerosing cholangitis – the black box of hepatology with multiple therapeutic strategies under development"

Tarik Asselah

Hospital Beaujon, France

"Emerging therapies for Hepatitis D and long-term outcomes of antiviral treatment in chronic viral hepatitis"

George Lau

Humanity and Health Medical Center, Hong Kong, China

"Plenary Lecture: Systemic therapy for HCC-Asian perspective"

 
 

Richard Finn

University of California Los Angeles, USA

"HCC: the path to molecular targeting: HCC is a "drugable" cancer "

Adam Gehring

UHN Toronto, Canada

"Curing HBV by safely modifying the immune system"

Fabian Zoulim

Lyon University, France

"Plenary Lecture: Gene editing and epigenetic modification for HBV cure"